Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034
Description
The Europe glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 7.09 Billion in 2024, driven by the rising prevalence rates of type 2 diabetes and obesity along with the supportive regulatory systems in the region. The market is anticipated to grow at a CAGR of 7.30% during the forecast period of 2025-2034, with the values likely to reach USD 14.34 Billion by 2034.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview
In Europe, many countries are adopting GLP-1 drugs as a key treatment for blood sugar control and weight management. This is augmenting the demand for leading therapies like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and dulaglutide (Trulicity). Further, the market is shifting toward oral and long-acting GLP-1 formulations, as patients prefer fewer injections and more convenient treatment options. Moreover, the increasing government support, ongoing drug innovation, and expanding insurance coverage are projected to fuel the GLP-1 market growth in the region.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Growth Drivers
Rising Prevalence of Diabetes to Support Market Growth
In the United Kingdom, over 5.8 million people are estimated to be living with diabetes. With nearly 4.6 million diagnosed cases and 1.3 million estimated to be undiagnosed type 2 diabetes patients, the demand for advanced diabetes treatments is increasing. The rising diabetes burden is driving higher adoption of GLP-1 receptor agonists, such as Ozempic, Mounjaro, and Trulicity, across Europe. Moreover, with pharmaceutical companies investing in production and clinical trials, the European market for GLP-1 is set to grow further in the coming years.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Substantial Investments in GLP-1 Peptide Manufacturing
In March 2025, CordenPharma, a contract development and manufacturing organization (CDMO), announced its initiative to invest over Euro 500 million to build a new peptide development and manufacturing site in Muttenz, Basel region. This investment will boost Europe's capacity for GLP-1 drug production, reinforcing its position as a key manufacturing hub. Moreover, the ongoing infrastructure expansion is anticipated to meet the growing Europe glucagon-like peptide-1 (GLP-1) agonists market demand in the coming years.
Growth in Strategic Partnerships
A major market trend is the rise in strategic partnerships to accelerate the development of next-generation GLP-1 therapies. For instance, in November 2024, Novo Nordisk struck a USD 285 million deal with Ascendis Pharma in order to advance a once-monthly GLP-1 receptor agonist for obesity and diabetes treatment. Through this partnership, Novo Nordisk plans to leverage Ascendis’ TransCon platform to develop long-acting metabolic disease treatments.
Development of Next-Generation GLP-1 Drug Delivery Systems
One of the major market trends is the rising focus on the development of next-generation GLP-1 drug delivery systems. Pharmaceutical companies are advancing drug delivery methods to improve patient convenience and treatment adherence. Longer-acting versions, including biweekly and monthly GLP-1 formulations, are being tested to reduce injection frequency, and are expected to elevate the Europe glucagon-like peptide-1 (GLP-1) agonists market value in the coming years.
Rising Obesity Rates
The rising obesity rates in European countries are contributing to the growth of the GLP-1 receptor agonists market, as more patients seek effective weight management solutions. According to the 2022 Health Survey for England, about 28% of adults were reported to be obese, and an additional 36% were overweight. This growing obesity burden is driving demand for GLP-1 drugs like Wegovy and Mounjaro, which are proven to aid weight loss and improve metabolic health.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
Segmentation Based on Drugs to Witness Substantial Growth
Based on the drugs, the Europe market is segmented into dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. The semaglutide segment holds a significant market share owing to the increasing adoption of the drug for diabetes and obesity treatment coupled with the rising availability of oral and long-acting semaglutide formulations in the region. Dulaglutide, a once-weekly GLP-1 drug for type 2 diabetes, is also widely used across Europe (particularly in Western Europe), due to its cardiovascular benefits and strong physician preference.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis by Region
Western Europe, including countries like Germany, France, the United Kingdom, Italy, and Spain, covers a substantial market share owing to the well-established healthcare systems and government support for GLP-1 drug coverage. The demand for long-acting and oral GLP-1 treatments is also rising in Central Europe as patients are increasingly preferring more convenient options. In Eastern Europe, consumer awareness and availability of GLP-1 therapies are improving, which is likely to impact market dynamics. Further, the Nordic region, led by Denmark, Sweden, and Norway, has a high demand for GLP-1 drugs, particularly due to Novo Nordisk’s strong presence in Denmark.
Leading Players in the Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company
Eli Lilly is a key player in the market, especially through its anti-obesity drug Mounjaro. This dual GIP/GLP-1 receptor agonist has demonstrated superior efficacy in glycemic control and weight management compared to traditional GLP-1 therapies. The company is focused on expanding its Europe glucagon-like peptide-1 (GLP-1) agonists market presence through regulatory approvals, clinical trials, and partnerships with healthcare providers.
Sanofi
Sanofi is a French multinational pharmaceutical company headquartered in Paris. It is one of the world's largest drug manufacturers, with a strong presence in diabetes care. The company continues to explore innovative delivery mechanisms and combination therapies for GLP-1 receptor agonists to improve patient adherence and treatment outcomes.
Novo Nordisk A/S
Novo Nordisk, based in Denmark, is a global leader in diabetes care and metabolic disorders. The company is actively investing in R&D, supply chain expansion, and physician education to drive the adoption of its GLP-1 receptor agonist drug candidates (such as Ozempic, Rybelsus, and Wegovy) across Europe.
AstraZeneca plc
AstraZeneca is a British-Swedish multinational pharmaceutical company headquartered in Cambridge, United Kingdom. It specializes in oncology, cardiovascular diseases, respiratory conditions, and metabolic disorders. The company is involved in diabetes treatment through GLP-1 receptor agonists and combination therapies.
Other key players in the market include Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc.
Key Questions Answered in the Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview
In Europe, many countries are adopting GLP-1 drugs as a key treatment for blood sugar control and weight management. This is augmenting the demand for leading therapies like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and dulaglutide (Trulicity). Further, the market is shifting toward oral and long-acting GLP-1 formulations, as patients prefer fewer injections and more convenient treatment options. Moreover, the increasing government support, ongoing drug innovation, and expanding insurance coverage are projected to fuel the GLP-1 market growth in the region.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Growth Drivers
Rising Prevalence of Diabetes to Support Market Growth
In the United Kingdom, over 5.8 million people are estimated to be living with diabetes. With nearly 4.6 million diagnosed cases and 1.3 million estimated to be undiagnosed type 2 diabetes patients, the demand for advanced diabetes treatments is increasing. The rising diabetes burden is driving higher adoption of GLP-1 receptor agonists, such as Ozempic, Mounjaro, and Trulicity, across Europe. Moreover, with pharmaceutical companies investing in production and clinical trials, the European market for GLP-1 is set to grow further in the coming years.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Substantial Investments in GLP-1 Peptide Manufacturing
In March 2025, CordenPharma, a contract development and manufacturing organization (CDMO), announced its initiative to invest over Euro 500 million to build a new peptide development and manufacturing site in Muttenz, Basel region. This investment will boost Europe's capacity for GLP-1 drug production, reinforcing its position as a key manufacturing hub. Moreover, the ongoing infrastructure expansion is anticipated to meet the growing Europe glucagon-like peptide-1 (GLP-1) agonists market demand in the coming years.
Growth in Strategic Partnerships
A major market trend is the rise in strategic partnerships to accelerate the development of next-generation GLP-1 therapies. For instance, in November 2024, Novo Nordisk struck a USD 285 million deal with Ascendis Pharma in order to advance a once-monthly GLP-1 receptor agonist for obesity and diabetes treatment. Through this partnership, Novo Nordisk plans to leverage Ascendis’ TransCon platform to develop long-acting metabolic disease treatments.
Development of Next-Generation GLP-1 Drug Delivery Systems
One of the major market trends is the rising focus on the development of next-generation GLP-1 drug delivery systems. Pharmaceutical companies are advancing drug delivery methods to improve patient convenience and treatment adherence. Longer-acting versions, including biweekly and monthly GLP-1 formulations, are being tested to reduce injection frequency, and are expected to elevate the Europe glucagon-like peptide-1 (GLP-1) agonists market value in the coming years.
Rising Obesity Rates
The rising obesity rates in European countries are contributing to the growth of the GLP-1 receptor agonists market, as more patients seek effective weight management solutions. According to the 2022 Health Survey for England, about 28% of adults were reported to be obese, and an additional 36% were overweight. This growing obesity burden is driving demand for GLP-1 drugs like Wegovy and Mounjaro, which are proven to aid weight loss and improve metabolic health.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
- Dulaglutide
- Exenatide
- Liraglutide
- Tirzepatide
- Lixisenatide
- Semaglutide
- Type 2 Diabetes Mellitus
- Obesity
- Parenteral
- Oral
- Hospitals
- Specialty Clinics
- Academic and Research Institutes
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- United Kingdom
- Germany
- France
- Italy
- Others
Segmentation Based on Drugs to Witness Substantial Growth
Based on the drugs, the Europe market is segmented into dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. The semaglutide segment holds a significant market share owing to the increasing adoption of the drug for diabetes and obesity treatment coupled with the rising availability of oral and long-acting semaglutide formulations in the region. Dulaglutide, a once-weekly GLP-1 drug for type 2 diabetes, is also widely used across Europe (particularly in Western Europe), due to its cardiovascular benefits and strong physician preference.
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis by Region
Western Europe, including countries like Germany, France, the United Kingdom, Italy, and Spain, covers a substantial market share owing to the well-established healthcare systems and government support for GLP-1 drug coverage. The demand for long-acting and oral GLP-1 treatments is also rising in Central Europe as patients are increasingly preferring more convenient options. In Eastern Europe, consumer awareness and availability of GLP-1 therapies are improving, which is likely to impact market dynamics. Further, the Nordic region, led by Denmark, Sweden, and Norway, has a high demand for GLP-1 drugs, particularly due to Novo Nordisk’s strong presence in Denmark.
Leading Players in the Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company
Eli Lilly is a key player in the market, especially through its anti-obesity drug Mounjaro. This dual GIP/GLP-1 receptor agonist has demonstrated superior efficacy in glycemic control and weight management compared to traditional GLP-1 therapies. The company is focused on expanding its Europe glucagon-like peptide-1 (GLP-1) agonists market presence through regulatory approvals, clinical trials, and partnerships with healthcare providers.
Sanofi
Sanofi is a French multinational pharmaceutical company headquartered in Paris. It is one of the world's largest drug manufacturers, with a strong presence in diabetes care. The company continues to explore innovative delivery mechanisms and combination therapies for GLP-1 receptor agonists to improve patient adherence and treatment outcomes.
Novo Nordisk A/S
Novo Nordisk, based in Denmark, is a global leader in diabetes care and metabolic disorders. The company is actively investing in R&D, supply chain expansion, and physician education to drive the adoption of its GLP-1 receptor agonist drug candidates (such as Ozempic, Rybelsus, and Wegovy) across Europe.
AstraZeneca plc
AstraZeneca is a British-Swedish multinational pharmaceutical company headquartered in Cambridge, United Kingdom. It specializes in oncology, cardiovascular diseases, respiratory conditions, and metabolic disorders. The company is involved in diabetes treatment through GLP-1 receptor agonists and combination therapies.
Other key players in the market include Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc.
Key Questions Answered in the Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report
- What was the Europe glucagon-like peptide-1 (GLP-1) agonists market value in 2024?
- What is the Europe glucagon-like peptide-1 (GLP-1) agonists market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on drugs?
- What is the market segmentation based on application?
- What is the market breakup based on the route of administration?
- What is the market breakup by end user?
- What is the market breakup based on the distribution channel?
- What major factors aid the Europe glucagon-like peptide-1 (GLP-1) agonists market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the Europe glucagon-like peptide-1 (GLP-1) agonists market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
300 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview
- 3.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview
- 3.1.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Historical Value (2018-2024)
- 3.1.2 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Forecast Value (2025-2034)
- 3.2 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview
- 3.2.1 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Historical Value (2018-2024)
- 3.2.2 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Landscape*
- 5.1 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market: Product Landscape
- 5.2.1 Analysis By Drugs
- 5.2.2 Analysis By Application
- 5.2.3 Analysis By Route of Administration
- 6 Clinical Trials and Pipeline Analysis
- 6.1 Analysis by Trial Registration Year
- 6.2 Analysis by Trial Status
- 6.3 Analysis by Trial Phase
- 6.4 Analysis by Therapeutic Area
- 6.5 Analysis by Geography
- 6.6 Drug Pipeline Assessment
- 7 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Dynamics
- 7.1 Market Drivers and Constraints
- 7.2 SWOT Analysis
- 7.2.1 Strengths
- 7.2.2 Weaknesses
- 7.2.3 Opportunities
- 7.2.4 Threats
- 7.3 PESTEL Analysis
- 7.3.1 Political
- 7.3.2 Economic
- 7.3.3 Social
- 7.3.4 Technological
- 7.3.5 Legal
- 7.3.6 Environment
- 7.4 Porter’s Five Forces Model
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of New Entrants
- 7.4.4 Threat of Substitutes
- 7.4.5 Degree of Rivalry
- 7.5 Key Demand Indicators
- 7.6 Key Price Indicators
- 7.7 Industry Events, Initiatives, and Trends
- 7.8 Value Chain Analysis
- 8 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
- 8.1 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 8.1.1 Market Overview
- 8.1.2 Dulaglutide
- 8.1.3 Exenatide
- 8.1.4 Liraglutide
- 8.1.5 Tirzepatide
- 8.1.6 Lixisenatide
- 8.1.7 Semaglutide
- 8.2 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
- 8.2.1 Market Overview
- 8.2.2 Type 2 Diabetes Mellitus
- 8.2.3 Obesity
- 8.3 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
- 8.3.1 Market Overview
- 8.3.2 Parenteral
- 8.3.3 Oral
- 8.4 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospitals
- 8.4.3 Specialty Clinics
- 8.4.4 Academic and Research Institutes
- 8.4.5 Others
- 8.5 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
- 8.5.1 Market Overview
- 8.5.2 Hospital Pharmacies
- 8.5.3 Retail Pharmacies
- 8.5.4 Online Pharmacies
- 8.6 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
- 8.6.1 United Kingdom
- 8.6.1.1 United Kingdom Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 8.6.2 Germany
- 8.6.2.1 Germany Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 8.6.3 France
- 8.6.3.1 France Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 8.6.4 Italy
- 8.6.4.1 Italy Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 8.6.5 Others
- 9 Regulatory Framework
- 10 Patent Analysis
- 10.1 Analysis By Drug Type of Patent
- 10.2 Analysis by Publication Year
- 10.3 Analysis by Issuing Authority
- 10.4 Analysis by Patent Age
- 10.5 Analysis by CPC Analysis
- 10.6 Analysis by Patent Valuation
- 11 Grants Analysis
- 11.1 Analysis by Year
- 11.2 Analysis by Amount Awarded
- 11.3 Analysis by Issuing Authority
- 11.4 Analysis by Grant Application
- 11.5 Analysis by Funding Institute
- 11.6 Analysis by NIH Departments
- 11.7 Analysis by Recipient Organization
- 12 Funding and Investment Analysis
- 12.1 Analysis by Funding Instances
- 12.2 Analysis by Drug Class of Funding
- 12.3 Analysis by Funding Amount
- 12.4 Analysis by Leading Players
- 12.5 Analysis by Leading Investors
- 12.6 Analysis by Geography
- 13 Strategic Initiatives
- 13.1 Analysis by Partnership Instances
- 13.2 Analysis by Type of Initiatives
- 13.3 Analysis by Joint Ventures
- 13.4 Analysis by Leading Players
- 13.5 Analysis by Geography
- 14 Supplier Landscape
- 14.1 Market Share Analysis, By Region (Top 5 Companies)
- 14.2 Eli Lilly and Company
- 14.2.1 Financial Analysis
- 14.2.2 Product Portfolio
- 14.2.3 Demographic Reach and Achievements
- 14.2.4 Company News and Development
- 14.2.5 Certifications
- 14.3 Sanofi
- 14.3.1 Financial Analysis
- 14.3.2 Product Portfolio
- 14.3.3 Demographic Reach and Achievements
- 14.3.4 Company News and Development
- 14.3.5 Certifications
- 14.4 Novo Nordisk A/S
- 14.4.1 Financial Analysis
- 14.4.2 Product Portfolio
- 14.4.3 Demographic Reach and Achievements
- 14.4.4 Company News and Development
- 14.4.5 Certifications
- 14.5 AstraZeneca plc
- 14.5.1 Financial Analysis
- 14.5.2 Product Portfolio
- 14.5.3 Demographic Reach and Achievements
- 14.5.4 Company News and Development
- 14.5.5 Certifications
- 14.6 Pfizer Inc.
- 14.6.1 Financial Analysis
- 14.6.2 Product Portfolio
- 14.6.3 Demographic Reach and Achievements
- 14.6.4 Company News and Development
- 14.6.5 Certifications
- 14.7 Boehringer Ingelheim
- 14.7.1 Financial Analysis
- 14.7.2 Product Portfolio
- 14.7.3 Demographic Reach and Achievements
- 14.7.4 Company News and Development
- 14.7.5 Certifications
- 14.8 F. Hoffmann-La Roche
- 14.8.1 Financial Analysis
- 14.8.2 Product Portfolio
- 14.8.3 Demographic Reach and Achievements
- 14.8.4 Company News and Development
- 14.8.5 Certifications
- 14.9 Amgen Inc.
- 14.9.1 Financial Analysis
- 14.9.2 Product Portfolio
- 14.9.3 Demographic Reach and Achievements
- 14.9.4 Company News and Development
- 14.9.5 Certifications
- 14.10 GlaxoSmithKline plc
- 14.10.1 Financial Analysis
- 14.10.2 Product Portfolio
- 14.10.3 Demographic Reach and Achievements
- 14.10.4 Company News and Development
- 14.10.5 Certifications
- 15 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market – Distribution Model (Additional Insight)
- 15.1 Overview
- 15.2 Potential Distributors
- 15.3 Key Parameters for Distribution Partner Assessment
- 16 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
